Page 159 - Read Online

Page 78 Sadaf et al. J Transl Genet Genom 2022;6:63-83 https://dx.doi.org/10.20517/jtgg.2021.36

treatment.

DECLARATIONS
Authors’ contributions
Review paper writing and editing: Sadaf H, Hong H, Maqbool M, Emhoff K, Lin J, Yan S, Anwer F, Zhao J

Availability of data and materials
Not applicable.

Financial support and sponsorship
This work was financially supported by grants from: NCI R00 CA172292, 1R01CA251141 (to Zhao J) and
start-up funds (to Zhao J) and two Core Utilization Pilot Grants (to Zhao J) from the Clinical and
Translational Science Collaborative of Cleveland, V Foundation Scholar Award, American Society of
Hematology (ASH) bridge grant (to Zhao J), National Institutes of Health training grant T32 CA094186,
Training in Computational Genomic Epidemiology of Cancer (CoGEC) career development program (to
Lin J).

Conflicts of interest
Jianjun Zhao has a consulting role for Curio Science. Faiz Anwer has a consulting or advisory role for
Seattle Genetics, Incyte Corporation Speakers’ Bureau, Company: Incyte Corporation; receives travel and
accommodations expenses from Seattle Genetics, Incyte; receives honoraria from Incyte, Company: Seattle
Genetics; and received research funding from Seattle Genetics, Company: Celgene, Acetylon
Pharmaceuticals, Millennium, Astellas Pharma and AbbVie. The authors have no other relevant affiliations
or financial involvement with any organization or entity with a financial interest in or financial conflict with
the subject matter or materials discussed in the manuscript apart from those disclosed.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2022.

REFERENCES
1. Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical
implications. Nat Rev Clin Oncol 2017;14:100-13. DOI PubMed
2. Talley PJ, Chantry AD, Buckle CH. Genetics in myeloma: genetic technologies and their application to screening approaches in
myeloma. Br Med Bull 2015;113:15-30. DOI PubMed
3. Janz S, Zhan F, Sun F, et al. Germline risk contribution to genomic instability in multiple myeloma. Front Genet 2019;10:424. DOI
PubMed PMC
4. Liyanage M, Coleman A, du Manoir S, et al. Multicolour spectral karyotyping of mouse chromosomes. Nat Genet 1996;14:312-5.
DOI PubMed
5. Grade M, Difilippantonio MJ, Camps J. Patterns of Chromosomal Aberrations in Solid Tumors. Recent Results Cancer Res
2015;200:115-42. DOI PubMed PMC
6. Bahr GF. The fibrous structure of human chromosomes in relation to rearrangements and aberrations; a theoretical consideration. Fed
Proc 1975;34:2209-17. PubMed
7. Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011;471:467-72.
DOI PubMed PMC
8. Raffan E, Semple RK. Next generation sequencing--implications for clinical practice. Br Med Bull 2011;99:53-71. DOI
9. Went M, Kinnersley B, Sud A, et al. Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility
genes. Hum Genomics 2019;13:37. DOI PubMed PMC